Axsome Therapeutics (AXSM) Cash from Financing Activities (2015 - 2026)

Axsome Therapeutics' Cash from Financing Activities history runs 12 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 89.77% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $75.2 million (down 14.85% YoY), while the FY2025 annual figure was $101.5 million, up 75.42% from the prior year.
• Cash from Financing Activities came in at $3.0 million for Q1 2026 at Axsome Therapeutics, down from $16.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $246.1 million in Q2 2023 to a low of -$1.2 million in Q1 2024.
• A 5-year average of $45.8 million and a median of $29.3 million in 2025 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 712300.0% in 2024 and fell as far as 102.3% in 2024.
• Axsome Therapeutics' Cash from Financing Activities stood at $1.1 million in 2022, then tumbled by 100.19% to -$2000.0 in 2023, then soared by 712300.0% to $14.2 million in 2024, then climbed by 15.03% to $16.4 million in 2025, then sank by 81.73% to $3.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $3.0 million, $16.4 million, and $21.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison